Onyx Pharmaceuticals is a biopharmaceutical company that engaged in developing and commercializing innovative therapies for improving the lives of people who suffer from cancer. The company focused on developing novel medicines targeting key molecular pathways.
Onyx has an important and growing multiple myeloma franchise, with Kyprolis® (carfilzomib) for Injection that has already been approved in the United States. Onyx possesses three partnered oncology assets that include: Stivarga® (regorafenib) tablets (a Bayer compound), Nexavar® (sorafenib) tablets (an Onyx and Bayer HealthCare Pharmaceuticals, Inc. compound), and palbociclib (a Pfizer, Inc. compound). Onyx also possesses several oncology compounds in stages of clinical development.
Amgen, a company that is committed to unlocking the potential of biology for patients who are suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics, had acquired Onyx Pharmaceuticals in 2013.
